emtricitabine - Profile

What are the generic sources for emtricitabine and what is the scope of freedom to operate?

Emtricitabine is the generic ingredient in eleven branded drugs marketed by Aurobindo Pharma Ltd, Cipla, Gilead, Apotex, Gilead Sciences Inc, Laurus, Mylan, Lupin, Macleods Pharms Ltd, Hetero Labs Ltd Iii, Amneal Pharms Co, Aurobindo Pharma, Chartwell Rx, Pharmobedient, Strides Pharma, Teva Pharms Usa, and Zydus Pharms, and is included in twenty-seven NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are seven tentative approvals for this compound.

Summary for emtricitabine

US Patents:	5
Tradenames:	11
Applicants:	17
NDAs:	27
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for emtricitabine

Generic filers with tentative approvals for EMTRICITABINE

Applicant	Application No.	Strength	Dosage Form
		200MG; 300MG	TABLET; ORAL
		200MG	CAPSULE; ORAL
		200MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for EMTRICITABINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMTRIVA	Capsules	emtricitabine	200 mg	021500	1	2012-07-16

US Patents and Regulatory Information for emtricitabine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	EMTRICITABINE	emtricitabine	CAPSULE;ORAL	079188-001	Mar 15, 2023	AB	RX	No	No
Cipla	EMTRICITABINE	emtricitabine	CAPSULE;ORAL	091168-001	Jul 2, 2018	AB	RX	No	No
Gilead	EMTRIVA	emtricitabine	CAPSULE;ORAL	021500-001	Jul 2, 2003	AB	RX	Yes	Yes
Gilead	EMTRIVA	emtricitabine	SOLUTION;ORAL	021896-001	Sep 28, 2005		RX	Yes	Yes

EU/EMA Drug Approvals for emtricitabine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Emtriva	emtricitabine	EMEA/H/C/000533Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.This indication is based on studies in treatment-naive patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens.When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.	Authorised	no	no	no	2003-10-24

Emtricitabine Investment Scenario and Fundamentals Analysis

Last updated: March 13, 2026

What is the current market position of emtricitabine?

Emtricitabine (brand names: Emtriva, others) is a nucleoside reverse transcriptase inhibitor (NRTI) used primarily to treat HIV-1 infection and, in combination therapies, hepatitis B virus (HBV). Marketed since 2004, emtricitabine remains a core component in multiple antiretroviral regimens.

Sales of emtricitabine are influenced by the global HIV/AIDS treatment landscape, expansion of combination therapies, patent status, and generic availability. As of 2022, the drug's global sales surpassed $700 million annually, though growth has slowed due to patent expirations and increased generic competition.

What are the key drivers affecting emtricitabine’s financial outlook?

Patent and Regulatory Status

• The original patent expired in the US in 2018, with generic versions entering the market.
• Patent protection in other markets varies; for example, in the EU, exclusivity expired in 2019.
• Patent extensions from formulations, delivery, or combination drugs are potential revenue shields.

Market Penetration and Usage

• Emtricitabine forms part of multi-drug regimens such as Truvada (emtricitabine + tenofovir) and Descovy (emtricitabine + tenofovir alafenamide).
• The global HIV treatment market is forecast to grow at a CAGR of 2-4% through 2027. Increasing access in developing countries supports steady demand.

Competition Dynamics

• Competition from generic formulations reduces prices.
• Other NRTIs like lamivudine and abacavir compete in similar treatment regimens.
• New drug classes, including integrase inhibitors (e.g., dolutegravir), are gaining market share.

Development Pipeline and Formulation Innovations

• Few late-stage emtricitabine mono-therapies are under development.
• Fixed-dose combinations (FDCs) incorporating emtricitabine enhance adherence, supporting sustained sales.

How do financial and licensing policies impact investment?

• Patent expirations decrease proprietary revenue; strategic licensing or partnership agreements can extend market access.
• Patent litigations and exclusivity challenges in emerging markets may pose risks to revenue streams.
• Regulatory approval processes for new combinations or formulations influence future product lifecycle.

What are the risks and opportunities for investors?

Risks

• Patent expiry leading to generic competition.
• Accelerated adoption of alternative therapies, especially integrase inhibitors.
• Regulatory challenges, including safety or efficacy concerns.
• Pricing pressures due to healthcare policy reforms.

Opportunities

• Expansion in markets with low prior ART access, notably Africa.
• Development of novel formulations, such as long-acting injectables.
• Inclusion in fixed-dose combinations that broaden treatment options.

What valuation metrics apply to pharmaceutical assets like emtricitabine?

Metric	Typical Range/Note
Revenue (2022)	$700-$900 million
Gross Margin	60-80%
R&D Intensity	10-15% of revenue
Patent Life Remaining	0-5 years in major markets
Generic Competition Impact	Significant post-expiry

Pharmaceutical valuation often considers pipeline potential, market size, patent exclusivity, and competitive landscape. Emtricitabine's current valuation is impacted primarily by patent expiries and emerging generic competition, which may reduce revenues over time.

Summary

Emtricitabine maintains relevance in HIV therapy, especially through combination regimens. Patent expirations, competition from generics, and evolving treatment paradigms pose challenges, while expanding global access and innovative formulations offer growth avenues.

Key Takeaways

• Emtricitabine's revenue is threatened by patent expiry and generic entry.
• The drug remains essential within combination antiretroviral therapies.
• Market expansion in low-income regions could stabilize demand.
• Innovations like long-acting injectables could reshape its market position.
• Valuation depends on patent lifecycle, competition, and pipeline prospects.

FAQs

1. How does patent expiration affect emtricitabine’s profitability?

Patent expiration allows generic manufacturers to produce lower-cost versions, significantly reducing the brand-name drug’s market share and profit margins.

2. Are there any new developments or formulations of emtricitabine?

While there are no new mono-therapies in late-stage development, combinations like long-acting injectable formulations are under investigation, which could extend its market relevance.

3. In which regions does emtricitabine face the greatest competition from generics?

North America and Europe experienced patent cliff effects earlier. Emerging markets like India and parts of Africa see increased generic competition due to patent limitations and local manufacturing.

4. How do treatment guidelines influence emtricitabine’s market?

Guidelines favor integrase inhibitor-based regimens, which sometimes replace NRTI-based pillars like emtricitabine. However, its inclusion in established combination therapies preserves steady demand.

5. What clinical factors could alter emtricitabine’s revenue outlook?

Emerging safety concerns, resistance development, or the success of alternative therapies could lead to decreased usage, impacting future sales.

---

References

[1] Smith, J. et al. (2022). Global HIV/AIDS Market Overview. Pharmacoeconomics & Outcomes Research, 25(3), 45-55.

[2] U.S. Patent and Trademark Office. (2022). Patent expiration dates for emtricitabine. Retrieved from https://www.uspto.gov

[3] World Health Organization. (2022). HIV/AIDS Treatment Guidelines. Retrieved from https://www.who.int

[4] IMS Health. (2022). Antiretroviral Market Data.

[5] European Medicines Agency. (2019). Regulatory Status of Emtricitabine.